Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oral Fludarabine Gives Antisoma Breathing Room

This article was originally published in The Pink Sheet Daily

Executive Summary

Antisoma’s deal with Sanofi-Aventis provides two years of cash, allowing the biotech to focus on its pipeline.

You may also be interested in...



Antisoma To Cut Costs After Another Phase III Failure Of A Lead Compound

Antisoma could cut jobs in the U.S. and the U.K. following the failure of its potential secondary acute myeloid leukemia therapy in a Phase III clinical trial.

Antisoma To Cut Costs After Another Phase III Failure Of A Lead Compound

Antisoma could cut jobs in the U.S. and the U.K. following the failure of its potential secondary acute myeloid leukemia therapy in a Phase III clinical trial.

Ahead of ASCO, Exelixis Inks Lucrative Deal With Sanofi For Its PI3 Kinase Inhibitors

Exelixis cashes in on a hot therapeutic drug target, showing that an R&D-focused biotech can succeed in the marketplace.

Related Content

Topics

UsernamePublicRestriction

Register

LL1126230

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel